Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Fletcher Aaron G.L.. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at Fletcher Aaron G.L. har rapporteret besiddelser eller handler i følgende virksomheder:
Sikkerhed | Titel | Senest indberettede beholdninger |
---|---|---|
Director, 10% Owner | 196.428 | |
US:CGTX / Cognition Therapeutics, Inc. | Director, 10% Owner | 48.500 |
US:LTRN / Lantern Pharma Inc. | 10% Owner | 118.626 |
US:AZTR / Azitra, Inc. | 10% Owner | 436.173 |
US:INAB / IN8bio, Inc. | Director, 10% Owner | 570.724 |
US:TFFP / TFF Pharmaceuticals, Inc. | Director | 143.470 |
US:CUE / Cue Biopharma, Inc. | Director | 940.000 |
US:SWKH / SWK Holdings Corporation | Director | 9.873 |
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Fletcher Aaron G.L.. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb AZTR / Azitra, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AZTR / Azitra, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg AZTR / Azitra, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AZTR / Azitra, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb CGTX / Cognition Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AZTR / Azitra, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CGTX / Cognition Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AZTR / Azitra, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-10-13 | CGTX | Fletcher Aaron G.L. | 90 | 12,0000 | 90 | 12,0000 | 1.083 | 252 | 1.5000 | -948 | -87,53 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb CUE / Cue Biopharma, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AZTR / Azitra, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CUE / Cue Biopharma, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AZTR / Azitra, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb INAB / IN8bio, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AZTR / Azitra, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg INAB / IN8bio, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AZTR / Azitra, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb LTRN / Lantern Pharma Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AZTR / Azitra, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg LTRN / Lantern Pharma Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AZTR / Azitra, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SWKH / SWK Holdings Corporation – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AZTR / Azitra, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SWKH / SWK Holdings Corporation – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AZTR / Azitra, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af Fletcher Aaron G.L. som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-06-30 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
P - Purchase | 71.428 | 196.428 | 57,14 | 7,00 | 499.996 | 1.374.996 | |
2025-06-20 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
A - Award | 34.000 | 48.500 | 234,48 | ||||
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -6.601 | 118.626 | -5,27 | 3,38 | -22.311 | 400.956 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -21.557 | 387.396 | -5,27 | 3,38 | -72.863 | 1.309.398 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -2.886 | 51.860 | -5,27 | 3,38 | -9.755 | 175.287 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -18.678 | 335.654 | -5,27 | 3,38 | -63.132 | 1.134.511 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -10.925 | 196.323 | -5,27 | 3,38 | -36.926 | 663.572 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -103 | 125.227 | -0,08 | 3,40 | -350 | 425.772 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -338 | 408.953 | -0,08 | 3,40 | -1.149 | 1.390.440 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -45 | 54.746 | -0,08 | 3,40 | -153 | 186.136 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -293 | 354.332 | -0,08 | 3,40 | -996 | 1.204.729 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -171 | 207.248 | -0,08 | 3,40 | -581 | 704.643 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -2 | 125.330 | 0,00 | 3,40 | -7 | 426.122 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -5 | 409.291 | 0,00 | 3,40 | -17 | 1.391.589 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -5 | 409.291 | 0,00 | 3,40 | -17 | 1.391.589 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -1 | 54.791 | 0,00 | 3,40 | -3 | 186.289 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -3 | 207.419 | 0,00 | 3,40 | -10 | 705.225 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -4.354 | 114.272 | -3,67 | 3,09 | -13.454 | 353.100 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -14.218 | 373.178 | -3,67 | 3,09 | -43.934 | 1.153.120 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -1.903 | 49.957 | -3,67 | 3,09 | -5.880 | 154.367 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -12.319 | 323.335 | -3,67 | 3,09 | -38.066 | 999.105 | |
2025-06-13 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -7.206 | 189.117 | -3,67 | 3,09 | -22.267 | 584.372 | |
2025-05-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -2.199 | 125.332 | -1,72 | 3,03 | -6.663 | 379.756 | |
2025-05-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -7.180 | 409.296 | -1,72 | 3,03 | -21.755 | 1.240.167 | |
2025-05-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -961 | 54.792 | -1,72 | 3,03 | -2.912 | 166.020 | |
2025-05-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -6.221 | 354.630 | -1,72 | 3,03 | -18.850 | 1.074.529 | |
2025-05-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -3.639 | 207.422 | -1,72 | 3,03 | -11.026 | 628.489 | |
2025-05-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -1.632 | 127.531 | -1,26 | 2,87 | -4.684 | 366.014 | |
2025-05-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -5.332 | 416.476 | -1,26 | 2,87 | -15.303 | 1.195.286 | |
2025-05-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -714 | 55.753 | -1,26 | 2,87 | -2.049 | 160.011 | |
2025-05-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -4.620 | 360.851 | -1,26 | 2,87 | -13.259 | 1.035.642 | |
2025-05-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -2.702 | 211.061 | -1,26 | 2,87 | -7.755 | 605.745 | |
2025-05-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -2.290 | 129.163 | -1,74 | 3,05 | -6.984 | 393.947 | |
2025-05-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -7.478 | 421.808 | -1,74 | 3,05 | -22.808 | 1.286.514 | |
2025-05-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -1.000 | 56.467 | -1,74 | 3,05 | -3.050 | 172.224 | |
2025-05-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -6.479 | 365.471 | -1,74 | 3,05 | -19.761 | 1.114.687 | |
2025-05-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -3.790 | 213.763 | -1,74 | 3,05 | -11.560 | 651.977 | |
2024-08-20 |
|
4/A | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
S - Sale | -2.324 | 131.248 | -1,74 | 8,00 | -18.592 | 1.049.984 | |
2024-08-20 |
|
4/A | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
S - Sale | -17.361 | 980.433 | -1,74 | 8,00 | -138.888 | 7.843.464 | |
2024-08-20 |
|
4/A | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
S - Sale | -5.314 | 300.143 | -1,74 | 8,00 | -42.512 | 2.401.144 | |
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
S - Sale | -2.324 | 131.248 | -1,74 | 9,00 | -20.916 | 1.181.232 | |
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
X - Other | 3.528 | 133.572 | 2,71 | 5,27 | 18.593 | 703.924 | |
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
S - Sale | -17.361 | 980.433 | -1,74 | 9,00 | -156.249 | 8.823.897 | |
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
X - Other | 26.355 | 997.794 | 2,71 | 5,27 | 138.891 | 5.258.374 | |
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
S - Sale | -5.314 | 300.143 | -1,74 | 9,00 | -47.826 | 2.701.287 | |
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
X - Other | 8.068 | 305.457 | 2,71 | 5,27 | 42.518 | 1.609.758 | |
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 573.394 | 573.394 | |||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 78.267 | 404.814 | 23,97 | ||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 484.638 | 2.506.667 | 23,97 | ||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 74.202 | 383.791 | 23,97 | ||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 2.094.650 | 2.094.650 | |||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 326.547 | 326.547 | |||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 2.022.029 | 2.022.029 | |||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 309.589 | 309.589 | |||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 44.559 | 130.044 | 52,12 | ||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 332.867 | 971.439 | 52,13 | ||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 101.900 | 297.389 | 52,13 | ||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 147.047 | 300.749 | 95,67 | ||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 23.628 | 85.485 | 38,20 | ||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 176.499 | 638.572 | 38,20 | ||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 54.032 | 195.489 | 38,20 | ||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 153.702 | 153.702 | |||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 61.857 | 61.857 | |||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 462.073 | 462.073 | |||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 141.457 | 141.457 | |||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 307.538 | 307.538 | |||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 525.797 | 525.797 | |||||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
P - Purchase | 125.000 | 125.000 | 8,00 | 1.000.000 | 1.000.000 | ||
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
P - Purchase | 375.000 | 1.259.427 | 42,40 | 8,00 | 3.000.000 | 10.075.416 | |
2024-08-14 |
|
4 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
C - Conversion | 884.427 | 884.427 | |||||
2024-08-12 | 3 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
84.917 | ||||||||
2024-08-12 | 3 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
60.973 | ||||||||
2024-08-12 | 3 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
8.056 | ||||||||
2024-08-12 | 3 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
8.056 | ||||||||
2024-08-12 | 3 | ACTU |
ACTUATE THERAPEUTICS, INC.
Common Stock |
69.375 | ||||||||
2024-06-11 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
A - Award | 8.500 | 14.500 | 141,67 | ||||
2024-05-28 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -4.253 | 131.453 | -3,13 | 6,33 | -26.921 | 832.097 | |
2024-05-28 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -13.888 | 429.286 | -3,13 | 6,33 | -87.911 | 2.717.380 | |
2024-05-28 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -1.859 | 57.467 | -3,13 | 6,33 | -11.767 | 363.766 | |
2024-05-28 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -2.126 | 135.706 | -1,54 | 6,25 | -13.288 | 848.162 | |
2024-05-28 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -6.944 | 443.174 | -1,54 | 6,25 | -43.400 | 2.769.838 | |
2024-05-28 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -930 | 59.326 | -1,54 | 6,25 | -5.812 | 370.788 | |
2024-02-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -4.185 | 137.832 | -2,95 | 4,87 | -20.381 | 671.242 | |
2024-02-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -13.686 | 450.118 | -2,95 | 4,87 | -66.651 | 2.192.075 | |
2024-02-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -1.832 | 60.256 | -2,95 | 4,87 | -8.922 | 293.447 | |
2024-02-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -15.780 | 142.017 | -10,00 | 4,85 | -76.533 | 688.782 | |
2024-02-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -51.608 | 463.804 | -10,01 | 4,85 | -250.299 | 2.249.449 | |
2024-02-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -6.909 | 62.088 | -10,01 | 4,85 | -33.509 | 301.127 | |
2024-02-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -10.620 | 157.797 | -6,31 | 4,40 | -46.728 | 694.307 | |
2024-02-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -34.731 | 515.412 | -6,31 | 4,40 | -152.816 | 2.267.813 | |
2024-02-29 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -4.649 | 68.997 | -6,31 | 4,40 | -20.456 | 303.587 | |
2024-01-19 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -12.521 | 168.417 | -6,92 | 4,20 | -52.588 | 707.351 | |
2024-01-19 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
X - Other | 16.801 | 180.938 | 10,24 | 3,13 | 52.587 | 566.336 | |
2024-01-19 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -40.893 | 550.143 | -6,92 | 4,20 | -171.751 | 2.310.601 | |
2024-01-19 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
X - Other | 54.873 | 591.036 | 10,23 | 3,13 | 171.752 | 1.849.943 | |
2024-01-19 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -5.475 | 73.646 | -6,92 | 4,20 | -22.995 | 309.313 | |
2024-01-19 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
X - Other | 7.347 | 79.121 | 10,24 | 3,13 | 22.996 | 247.649 | |
2023-12-01 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -91.708 | 371.950 | -19,78 | 3,44 | -315.476 | 1.279.508 | |
2023-12-01 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -53.640 | 217.553 | -19,78 | 3,44 | -184.522 | 748.382 | |
2023-11-13 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
A - Award | 500.095 | 500.095 | 1,05 | 525.100 | 525.100 | ||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
C - Conversion | 436.173 | 436.173 | |||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
C - Conversion | 25.280 | 137.000 | 22,63 | ||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
C - Conversion | 111.720 | 111.720 | |||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
C - Conversion | 188.810 | 1.023.442 | 22,62 | ||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
C - Conversion | 834.632 | 834.632 | |||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
C - Conversion | 57.747 | 313.250 | 22,60 | ||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
C - Conversion | 255.503 | 255.503 | |||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
C - Conversion | 799.467 | 799.467 | |||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
C - Conversion | 467.613 | 467.613 | |||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
C - Conversion | 144.705 | 426.944 | 51,27 | ||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
P - Purchase | 73.708 | 282.239 | 35,35 | 5,00 | 368.540 | 1.411.195 | |
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
P - Purchase | 208.531 | 208.531 | |||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Convertible Notes |
S - Sale | -82.223 | 0 | -100,00 | ||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
C - Conversion | 896.035 | 2.643.705 | 51,27 | ||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
P - Purchase | 456.412 | 1.747.670 | 35,35 | 5,00 | 2.282.060 | 8.738.350 | |
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
P - Purchase | 1.291.258 | 1.291.258 | |||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Convertible Notes |
S - Sale | -509.141 | 0 | -100,00 | ||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
C - Conversion | 137.186 | 404.767 | 51,27 | ||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
P - Purchase | 69.880 | 267.581 | 35,35 | 5,00 | 349.400 | 1.337.905 | |
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Common Stock |
P - Purchase | 197.701 | 197.701 | |||||
2023-06-23 |
|
4 | AZTR |
Azitra Inc
Convertible Notes |
S - Sale | -77.953 | 0 | -100,00 | ||||
2023-06-15 | 3 | AZTR |
Azitra Inc
Convertible Notes |
77.953 | ||||||||
2023-06-15 | 3 | AZTR |
Azitra Inc
Convertible Notes |
509.141 | ||||||||
2023-06-15 | 3 | AZTR |
Azitra Inc
Convertible Notes |
82.223 | ||||||||
2023-06-13 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
A - Award | 6.000 | 6.000 | |||||
2022-12-13 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 8.735 | 570.724 | 1,55 | 2,48 | 21.652 | 1.414.711 | |
2022-12-13 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 57.052 | 3.727.597 | 1,55 | 2,48 | 141.420 | 9.239.967 | |
2022-12-13 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 9.214 | 601.980 | 1,55 | 2,48 | 22.840 | 1.492.188 | |
2022-11-29 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
P - Purchase | 1.871 | 309.748 | 0,61 | 2,65 | 4.958 | 820.739 | |
2022-11-29 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
P - Purchase | 12.220 | 2.021.906 | 0,61 | 2,65 | 32.379 | 5.357.444 | |
2022-11-29 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
P - Purchase | 1.973 | 326.733 | 0,61 | 2,65 | 5.228 | 865.744 | |
2022-11-23 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 43.470 | 143.470 | 43,47 | 1,15 | 49.990 | 164.990 | |
2022-11-17 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
P - Purchase | 8.269 | 307.877 | 2,76 | 1,40 | 11.577 | 431.028 | |
2022-11-17 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
P - Purchase | 54.009 | 2.009.686 | 2,76 | 1,40 | 75.613 | 2.813.560 | |
2022-11-17 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
P - Purchase | 8.722 | 324.760 | 2,76 | 1,40 | 12.211 | 454.664 | |
2022-11-16 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
P - Purchase | 174.700 | 299.608 | 139,86 | 1,20 | 209.640 | 359.530 | |
2022-11-16 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
P - Purchase | 1.141.030 | 1.955.677 | 140,06 | 1,20 | 1.369.236 | 2.346.812 | |
2022-11-16 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
P - Purchase | 184.270 | 316.038 | 139,84 | 1,20 | 221.124 | 379.246 | |
2022-11-09 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -40.586 | 164.137 | -19,82 | 4,40 | -178.578 | 722.203 | |
2022-11-09 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -132.575 | 536.163 | -19,82 | 4,40 | -583.330 | 2.359.117 | |
2022-11-09 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -17.748 | 71.774 | -19,83 | 4,40 | -78.091 | 315.806 | |
2022-11-09 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -100.380 | 463.658 | -17,80 | 4,40 | -441.672 | 2.040.095 | |
2022-11-09 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -58.711 | 271.193 | -17,80 | 4,40 | -258.328 | 1.193.249 | |
2022-09-29 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 2.913 | 561.989 | 0,52 | 2,02 | 5.888 | 1.136.005 | |
2022-09-29 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 19.017 | 3.670.545 | 0,52 | 2,02 | 38.441 | 7.419.640 | |
2022-09-29 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 3.070 | 592.766 | 0,52 | 2,02 | 6.206 | 1.198.217 | |
2022-09-07 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -1.275 | 26.093 | -4,66 | 5,20 | -6.630 | 135.684 | |
2022-09-07 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
X - Other | 6.438 | 27.328 | 30,82 | 1,03 | 6.631 | 28.148 | |
2022-09-07 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
S - Sale | -5.170 | 20.930 | -19,81 | 5,20 | -26.884 | 108.836 | |
2022-09-07 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
X - Other | 26.100 | 26.100 | 1,03 | 26.883 | 26.883 | ||
2022-08-30 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 4.660 | 559.076 | 0,84 | 2,02 | 9.413 | 1.129.334 | |
2022-08-30 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 30.428 | 3.651.528 | 0,84 | 2,02 | 61.465 | 7.376.087 | |
2022-08-30 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 4.912 | 589.696 | 0,84 | 2,02 | 9.922 | 1.191.186 | |
2022-08-30 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 1.306 | 554.416 | 0,24 | 2,01 | 2.625 | 1.114.376 | |
2022-08-30 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 8.531 | 3.621.100 | 0,24 | 2,01 | 17.147 | 7.278.411 | |
2022-08-30 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 1.377 | 584.784 | 0,24 | 2,01 | 2.768 | 1.175.416 | |
2022-08-18 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 5.823 | 553.110 | 1,06 | 1,93 | 11.238 | 1.067.502 | |
2022-08-18 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 38.035 | 3.612.569 | 1,06 | 1,93 | 73.408 | 6.972.258 | |
2022-08-18 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 6.142 | 583.407 | 1,06 | 1,93 | 11.854 | 1.125.976 | |
2022-08-17 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 206.575 | 540.287 | 61,90 | 1,90 | 392.492 | 1.026.545 | |
2022-08-17 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 1.349.218 | 3.574.534 | 60,63 | 1,90 | 2.563.514 | 6.791.615 | |
2022-08-17 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
P - Purchase | 217.891 | 217.891 | 1,90 | 413.993 | 413.993 | ||
2022-05-25 |
|
4 | CUE |
Cue Biopharma, Inc.
Common Stock |
P - Purchase | 55.000 | 940.000 | 6,21 | 3,34 | 183.700 | 3.139.600 | |
2022-05-25 |
|
4 | CUE |
Cue Biopharma, Inc.
Common Stock |
P - Purchase | 150.000 | 885.000 | 20,41 | 3,52 | 528.000 | 3.115.200 | |
2022-05-17 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 24.600 | 109.600 | 28,94 | 5,08 | 124.968 | 556.768 | |
2022-05-17 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 85.000 | 85.000 | 4,86 | 413.100 | 413.100 | ||
2022-04-04 |
|
4 | CUE |
Cue Biopharma, Inc.
Common Stock |
P - Purchase | 735.000 | 735.000 | 4,76 | 3.498.600 | 3.498.600 | ||
2022-04-04 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 42.000 | 542.000 | 8,40 | 6,89 | 289.380 | 3.734.380 | |
2022-04-04 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 500.000 | 500.000 | 6,43 | 3.215.000 | 3.215.000 | ||
2022-03-21 |
|
4 | LTRN |
Lantern Pharma Inc.
Series A Warrants |
X - Other | -35.347 | 0 | -100,00 | ||||
2022-03-21 |
|
4 | LTRN |
Lantern Pharma Inc.
Series A Warrants |
X - Other | -60.432 | 0 | -100,00 | ||||
2022-03-21 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
X - Other | 35.347 | 329.904 | 12,00 | 110.636,11 | 3.910.654.580 | 36.499.295.233 | |
2022-03-21 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
X - Other | 60.432 | 564.038 | 12,00 | 189.152,16 | 11.430.843.333 | 106.689.006.022 | |
2022-02-01 |
|
4/A | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
C - Conversion | 1.424.014 | 1.424.014 | |||||
2022-02-01 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Stock Option (right to buy) |
J - Other | 1.145 | 1.145 | |||||
2022-02-01 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Stock Option (right to buy) |
J - Other | -1.145 | 2.719 | -29,63 | ||||
2022-01-12 |
|
4 | SWKH |
SWK Holdings Corp
Common Stock |
D - Sale to Issuer | -1.363 | 9.873 | -12,13 | ||||
2022-01-05 |
|
4 | CUE |
Cue Biopharma, Inc.
Stock Option (right to buy) |
A - Award | 10.000 | 10.000 | |||||
2022-01-03 |
|
4 | SWKH |
SWK Holdings Corp
Common Stock |
A - Award | 250 | 11.236 | 2,28 | ||||
2021-11-08 |
|
4 | LTRN |
Lantern Pharma Inc.
Stock Option |
A - Award | 3.200 | 3.200 | |||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Simple Agreement for Future Equity |
C - Conversion | -25.593 | 0 | -100,00 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Simple Agreement for Future Equity |
C - Conversion | -158.476 | 0 | -100,00 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Simple Agreement for Future Equity |
C - Conversion | -24.263 | 0 | -100,00 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Warrant (right to buy) |
X - Other | -33.495 | 0 | -100,00 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Series B-1 Convertible Preferred Stock |
C - Conversion | -111.504 | 0 | -100,00 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Series B-1 Convertible Preferred Stock |
C - Conversion | -1.930.673 | 0 | -100,00 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Series B-1 Convertible Preferred Stock |
C - Conversion | -134.626 | 0 | -100,00 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Series B-1 Convertible Preferred Stock |
C - Conversion | -110.744 | 0 | -100,00 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Series B-1 Convertible Preferred Stock |
C - Conversion | -1.138.040 | 0 | -100,00 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Series B-1 Convertible Preferred Stock |
C - Conversion | -827.275 | 0 | -100,00 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Series B-1 Convertible Preferred Stock |
C - Conversion | -253.256 | 0 | -100,00 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Series B Convertible Preferred Stock |
C - Conversion | -792.547 | 0 | -100,00 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Series B Convertible Preferred Stock |
C - Conversion | -1.355.017 | 0 | -100,00 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Series B Convertible Preferred Stock |
C - Conversion | -4.605.985 | 0 | -100,00 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
C - Conversion | 25.593 | 60.065 | 74,24 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
C - Conversion | 34.472 | 34.472 | |||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
P - Purchase | 144.530 | 899.905 | 19,13 | 12,00 | 1.734.360 | 10.798.860 | |
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
C - Conversion | 158.476 | 755.375 | 26,55 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
C - Conversion | 596.899 | 596.899 | |||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
P - Purchase | 22.129 | 88.012 | 33,59 | 12,00 | 265.548 | 1.056.144 | |
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
C - Conversion | 24.263 | 65.883 | 58,30 | ||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
C - Conversion | 41.620 | 41.620 | |||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
S - Sale | -90 | 385.248 | -0,02 | 12,00 | -1.083 | 4.622.976 | |
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
X - Other | 33.495 | 385.339 | 9,52 | 0,03 | 1.072 | 12.331 | |
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
C - Conversion | 351.844 | 351.844 | |||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
P - Purchase | 23.341 | 57.579 | 68,17 | 12,00 | 280.092 | 690.948 | |
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
C - Conversion | 34.238 | 34.238 | |||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
C - Conversion | 255.765 | 255.765 | |||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
C - Conversion | 78.298 | 78.298 | |||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
C - Conversion | 245.029 | 245.029 | |||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
C - Conversion | 418.926 | 418.926 | |||||
2021-10-15 |
|
4 | CGTX |
COGNITION THERAPEUTICS INC
Common Stock |
C - Conversion | 1.424.014 | 1.424.014 | |||||
2021-10-01 |
|
4 | SWKH |
SWK Holdings Corp
Common Stock |
A - Award | 1.363 | 10.986 | 14,16 | ||||
2021-10-01 |
|
4 | SWKH |
SWK Holdings Corp
Common Stock |
A - Award | 250 | 9.623 | 2,67 | ||||
2021-08-17 |
|
4 | INAB |
IN8BIO, INC.
Stock Option (right to buy) |
J - Other | 10.500 | 10.500 | |||||
2021-08-17 |
|
4 | INAB |
IN8BIO, INC.
Stock Option (right to buy) |
J - Other | 12.775 | 12.775 | |||||
2021-08-03 |
|
4 | INAB |
IN8BIO, INC.
Series A Preferred Stock |
C - Conversion | -326.795 | 0 | -100,00 | ||||
2021-08-03 |
|
4 | INAB |
IN8BIO, INC.
Series A Preferred Stock |
C - Conversion | -2.023.568 | 0 | -100,00 | ||||
2021-08-03 |
|
4 | INAB |
IN8BIO, INC.
Series A Preferred Stock |
C - Conversion | -309.823 | 0 | -100,00 | ||||
2021-08-03 |
|
4 | INAB |
IN8BIO, INC.
Series A Preferred Stock |
C - Conversion | -907.007 | 0 | -100,00 | ||||
2021-08-03 |
|
4 | INAB |
IN8BIO, INC.
Series A Preferred Stock |
C - Conversion | -228.438 | 0 | -100,00 | ||||
2021-08-03 |
|
4 | INAB |
IN8BIO, INC.
Series A Preferred Stock |
C - Conversion | -1.706.490 | 0 | -100,00 | ||||
2021-08-03 |
|
4 | INAB |
IN8BIO, INC.
Series A Preferred Stock |
C - Conversion | -522.355 | 0 | -100,00 | ||||
2021-08-03 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
C - Conversion | 359.374 | 359.374 | |||||
2021-08-03 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
C - Conversion | 2.225.316 | 2.225.316 | |||||
2021-08-03 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
C - Conversion | 340.712 | 340.712 | |||||
2021-08-03 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
C - Conversion | 997.433 | 997.433 | |||||
2021-08-03 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
C - Conversion | 251.211 | 251.211 | |||||
2021-08-03 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
C - Conversion | 1.876.624 | 1.876.624 | |||||
2021-08-03 |
|
4 | INAB |
IN8BIO, INC.
Common Stock |
C - Conversion | 574.432 | 574.432 | |||||
2021-06-30 |
|
4 | SWKH |
SWK Holdings Corp
Common Stock |
A - Award | 250 | 9.373 | 2,74 | ||||
2021-04-01 |
|
4 | SWKH |
SWK Holdings Corp
Common Stock |
A - Award | 250 | 9.123 | 2,82 | ||||
2021-01-06 |
|
4 | CUE |
Cue Biopharma, Inc.
Stock Option (right to buy) |
A - Award | 10.000 | 10.000 | |||||
2021-01-04 |
|
4 | SWKH |
SWK Holdings Corp
Common Stock |
A - Award | 250 | 8.873 | 2,90 | ||||
2020-11-25 |
|
4 | CUE |
Cue Biopharma, Inc.
Common Stock |
P - Purchase | 6.548 | 165.000 | 4,13 | 12,64 | 82.776 | 2.085.831 | |
2020-11-24 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 5.000 | 100.000 | 5,26 | 15,13 | 75.656 | 1.513.120 | |
2020-10-01 |
|
4 | SWKH |
SWK Holdings Corp
Common Stock |
A - Award | 1.661 | 8.623 | 23,86 | ||||
2020-10-01 |
|
4 | SWKH |
SWK Holdings Corp
Common Stock |
A - Award | 250 | 6.962 | 3,72 | ||||
2020-08-26 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Stock Options (Right to Purchase) |
A - Award | 20.000 | 159.429 | 14,34 | ||||
2020-07-02 |
|
4 | SWKH |
SWK Holdings Corp
Common Stock |
A - Award | 1.419 | 6.712 | 26,81 | ||||
2020-06-25 |
|
4 | CUE |
Cue Biopharma, Inc.
Common Stock |
P - Purchase | 2.953 | 158.452 | 1,90 | 25,24 | 74.534 | 3.999.328 | |
2020-06-25 |
|
4 | CUE |
Cue Biopharma, Inc.
Common Stock |
P - Purchase | 4.547 | 155.499 | 3,01 | 24,64 | 112.038 | 3.831.495 | |
2020-06-16 |
|
4 | LTRN |
Lantern Pharma Inc.
Stock Options |
J - Other | 9.135 | 9.135 | |||||
2020-06-16 |
|
4 | LTRN |
Lantern Pharma Inc.
Series A Preferred Stock |
C - Conversion | -35.181 | 0 | -100,00 | ||||
2020-06-16 |
|
4 | LTRN |
Lantern Pharma Inc.
Series A Preferred Stock |
C - Conversion | -262.806 | 0 | -100,00 | ||||
2020-06-16 |
|
4 | LTRN |
Lantern Pharma Inc.
Series A Preferred Stock |
C - Conversion | -80.454 | 0 | -100,00 | ||||
2020-06-16 |
|
4 | LTRN |
Lantern Pharma Inc.
Series A Preferred Stock |
C - Conversion | -169.286 | 0 | -100,00 | ||||
2020-06-16 |
|
4 | LTRN |
Lantern Pharma Inc.
Series A Preferred Stock |
C - Conversion | -289.429 | 0 | -100,00 | ||||
2020-06-16 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
C - Conversion | 61.214 | 89.522 | 216,24 | ||||
2020-06-16 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
C - Conversion | 457.282 | 668.738 | 216,25 | ||||
2020-06-16 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
C - Conversion | 139.989 | 204.723 | 216,25 | ||||
2020-06-16 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
C - Conversion | 294.557 | 294.557 | |||||
2020-06-16 |
|
4 | LTRN |
Lantern Pharma Inc.
Common Stock |
C - Conversion | 503.606 | 503.606 | |||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
369.232 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
515.954 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
332.806 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
369.232 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
515.954 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
332.806 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
369.232 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
515.954 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
332.806 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
369.232 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
515.954 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
332.806 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
369.232 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
515.954 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
332.806 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
369.232 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
515.954 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
332.806 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
369.232 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
515.954 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
332.806 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
369.232 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
515.954 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
332.806 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
369.232 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
515.954 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
332.806 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
369.232 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
515.954 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
332.806 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
369.232 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
515.954 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
332.806 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
369.232 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
515.954 | ||||||||
2020-06-10 | 3 | LTRN |
Lantern Pharma Inc.
Common Stock |
332.806 | ||||||||
2020-05-26 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 20.000 | 95.000 | 26,67 | 5,08 | 101.600 | 482.600 | |
2020-04-17 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 5.581 | 75.000 | 8,04 | 4,72 | 26.342 | 354.000 | |
2020-04-06 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 6.252 | 69.419 | 9,90 | 4,24 | 26.508 | 294.337 | |
2020-04-06 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 16.748 | 63.167 | 36,08 | 3,97 | 66.490 | 250.773 | |
2020-04-06 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 500 | 46.419 | 1,09 | 3,75 | 1.875 | 174.071 | |
2020-03-31 |
|
4 | SWKH |
SWK Holdings Corp
Common Stock |
A - Award | 1.500 | 5.293 | 39,55 | ||||
2020-01-06 |
|
4 | SWKH |
SWK Holdings Corp
Common Stock |
A - Award | 1.417 | 3.793 | 59,64 | ||||
2020-01-06 |
|
4 | CUE |
Cue Biopharma, Inc.
Stock Option (right to buy) |
A - Award | 8.000 | 8.000 | |||||
2019-12-03 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Stock Options (Right to Buy) |
A - Award | 3.623 | 139.429 | 2,67 | ||||
2019-10-29 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -43.919 | 135.806 | -24,44 | ||||
2019-10-29 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Warrants |
A - Award | 43.794 | 179.693 | 32,23 | ||||
2019-10-29 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 43.919 | 45.919 | 2.195,95 | ||||
2019-10-29 |
|
4 | TFFP |
TFF Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 2.000 | 2.000 | 5,00 | 10.000 | 10.000 | ||
2019-10-09 |
|
4 | SWKH |
SWK Holdings Corp
Common Stock |
A - Award | 1.931 | 2.376 | 433,93 | ||||
2019-10-07 |
|
4 | CUE |
Cue Biopharma, Inc.
Stock Option (right to buy) |
A - Award | 50.000 | 50.000 | |||||
2019-10-07 | 3 | CUE |
Cue Biopharma, Inc.
Common Stock |
310.771 | ||||||||
2019-10-07 | 3 | CUE |
Cue Biopharma, Inc.
Common Stock |
168.686 | ||||||||
2019-10-07 | 3 | CUE |
Cue Biopharma, Inc.
Common Stock |
310.771 | ||||||||
2019-10-07 | 3 | CUE |
Cue Biopharma, Inc.
Common Stock |
168.686 | ||||||||
2019-10-07 | 3 | CUE |
Cue Biopharma, Inc.
Common Stock |
310.771 | ||||||||
2019-10-07 | 3 | CUE |
Cue Biopharma, Inc.
Common Stock |
168.686 | ||||||||
2019-10-01 |
|
4 | SWKH |
SWK Holdings Corp
Common Stock |
A - Award | 445 | 445 |